ASSESSING THE RISK FACTORS AND COMPLICATIONS RELATED TO METABOLIC SYNDROME IN DIABETIC PATIENTS: A RETROSPECTIVE ANALYSIS FROM METABESITY MANAGEMENT CLINICS.
Main Article Content
Keywords
Type 2 Diabetes Mellitus (T2DM), Metabolic Syndrome (MetS), Risk Factors, Complications, Metabesity Management Clinics.
Abstract
Objective: This study aimed to assess the risk factors and complications related to Metabolic Syndrome in Type 2 Diabetes Mellitus (T2DM) patients presented at the Metabesity Management Clinics.
Methods: A retrospective cross-sectional study was conducted at two tertiary care centers over two years, including type 2 diabetic patients aged 18 and above. Patients with specific conditions or critical illnesses were excluded. Data, encompassing medical history, demographics, and various clinical measurements, were collected from medical records using Healthwire software.
Results: The analysis revealed hypertension (53.3%) as the predominant risk factor associated with MetS among T2DM patients. Furthermore, Diabetic Peripheral Neuropathy (40.0%) emerged as the most prevalent microvascular complication in this population. Lower extremity vascular health, assessed by DFA-TBPI (0.80 ± 0.19), demonstrated consistent results, while DFA-ABPI (1.06 ± 0.06) indicated stable blood flow. Neurological assessments revealed moderate sensory perception in both right (12.15) and left (12.97) feet, with notable variability. A significant proportion (33.2%) reported mild depression based on PHQ-9 outcomes. The categorical distribution based on the FIB-4 score indicated a high level in 1.0% of respondents, with 15.9% at an intermediate stage. Conversely, the NFS score demonstrated that 0.1% exhibited high fibrosis advancement, while 53.4% were at an intermediate level.
Conclusion: Hypertension was identified as the most prevalent risk factor and peripheral neuropathy as the most common microvascular complications associated with MetS among type 2 diabetes patients.
References
2. World Health Organization. Diabetes [internet]. [Updated 5 April 2023]. Available at: https://www.who.int/news-room/fact-sheets/detail/diabetes
3. Qidwai W, Ashfaq T. Imminent epidemic of diabetes mellitus in Pakistan: issues and challenges for health care providers. J Liaquat Univ Med Heal Sci. 2010;9(3): 112-113. Available at: http://ecommons.aku.edu/pakistan_fhs_mc_fam_med/64
4. Wehrli F, Taneri PE, Bano A, Bally L, Blekkenhorst LC, Bussler W, et al. Oat Intake and Risk of Type 2 Diabetes, Cardiovascular Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis. Nutrients. 2021; 13(8):2560. https://doi.org/10.3390/nu13082560
5. Nagamani S, Sahoo R, Muneeswaran G, Sastry GN. Data science driven drug repurposing for metabolic disorders. In Silico Drug Design 2019 Jan 1 (pp. 191-227). Academic Press. https://doi.org/10.1016/B978-0-12-816125-8.00007-9
6. Zimmet P, Alberti KG, Stern N, Bilu C, El‐Osta A, Einat H, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more!. J. Intern. Med. 2019;286(2):181-191. https://doi.org/10.1111/joim.12924
7. Belete R, Ataro Z, Abdu A, Sheleme M. Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021;13(1):25. doi: 10.1186/s13098-021-00641-8.
8. Prabhakaran P. Size at birth and later "metabesity". Indian Pediatr 2017; 54:453-454
9. Zaheer S, Fatima Zeb T, Baloch A, Amin R, Amjad Z, Sheikh A. The multifactorial burden of Type 2 Diabetes mellitus: a study from clinical settings of University Hospital, Karachi, Pakistan. IJEHSR. 2020;8(4):275-287. https://doi.org/10.29052/IJEHSR.v8.i4.2020.275-287
10. Carbone S, Del Buono MG, Ozemek C, Lavie CJ. Obesity, risk of diabetes and role of physical activity, exercise training and cardiorespiratory fitness. Prog Cardiovasc Dis. 2019;62(4):327-333. doi: 10.1016/j.pcad.2019.08.004.
11. Gao F, Wang ZJ, Shen H, Yang SW, Nie B, Zhou YJ. Impact of obesity on mortality in patients with diabetes: meta-analysis of 20 studies including 250,016 patients. J Diabetes Investig. 2018; 9(1):44–54. doi: 10.1111/jdi.12677
12. Misra A, Gopalan H, Jayawardena R, Hills AP, Soares M, Reza‐Albarrán AA, et al. Diabetes in developing countries. J Diabetes. 2019;11(7):522-539. doi: 10.1111/1753-0407.12913.
13. Lee J, Vali Y, Boursier J, Spijker R, Anstee QM, Bossuyt PM, et al. Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review. Liver Int. 2021;41(2):261-270. doi: 10.1111/liv.14669.
14. Metabesity Guidelines. JPMA. Volume 71, No.5, supplement 3, May 2021. Available at: https://www.jpma.org.pk/supplement-article-details/611
15. Balarini CM, Braga VA. New translational insights on metabolic syndrome: Obesity, hypertension, diabetes and beyond. Front. Physiol. 2016;7:229. Doi: 10.3389/fphys.2016.00229
16. Abera MA, Gebregziabher T, Tesfay H, Alemayehu M. Factors associated with the occurrence of hypertension and dyslipidemia among diabetic patients attending the diabetes clinic of Ayder Comprehensive Specialized Hospital, Mekelle, Ethiopia. East Afr J Health Sci. 2019;1(1):3-16.
17. Katsiki N, G Athyros V, Karagiannis A, P Mikhailidis D. Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. Current vascular pharmacology. 2014;12(4):627-641.
18. Katsiki N, Anagnostis P, Kotsa K, Goulis DG, Mikhailidis DP. Obesity, metabolic syndrome and the risk of microvascular complications in patients with diabetes mellitus. Curr. Pharm. Des. 2019;25(18):2051-2059. doi: 10.2174/1381612825666190708192134
19. Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care. 2006;29(12):2701-2707. doi: 10.2337/dc06-0942.
20. Maric C, Hall JE. Obesity, metabolic syndrome and diabetic nephropathy. Contrib Nephrol. 2011;170:28–35. doi: 10.1159/000324941
21. Islam MS, Chowdhury AA, Iqbal M, Assadujjaman M, Ahammed AS, Rahman MA, kumar Das S, Barman GC, Miah MO, Mazumder10 RC, Khan11 MS. Association of metabolic syndrome in type 2 diabetes patients with or without nephropathy. JSWMC. 2020;10(1):43-55.
22. Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Intern Med. 2003; 163: 427–436. doi: 10.1001/archinte.163.4.427.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Mujtaba Hasan
MBBS, FCPS, MRCP, FRCP, FRCPE, FCCP, Dept. of Medicine, Akhtar Saeed medical college, Lahore, Pakistan
Sadia Salman
MBBS, FCPS, Jinnah Hospital Lahore, Allama Iqbal medical college, Lahore, Pakistan
S. Abbas Raza
MBBS, FACE, Shaukat Khanum Memorial Cancer Hospital and Research Center, Lahore, Pakistan
Fawad Ahmad Randhawa
MBBS, FCPS, FACE, FRCP, King Edward Medical University, Lahore, Pakistan
Muhammad Asim Rana
MBBS, MRCP, FRCP, FCCP, EDIC, SFCCM, Amna Inayat Medical College/Bahria International Hospital, Lahore, Pakistan